Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Envista HoldingsNVST -2.65%79 EV-to-EBIT is 18.71 as of Aug. 06, 2026, which is 16% below its 10-year median of 22.33. GuruFocus rates NVST with a GF Score™ of 79/100 and a GF Value™ of $23.94 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 469 Medical Devices & Instruments companies, Envista Holdings ranks worse than 58.64% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Envista Holdings's Enterprise Value for the quarter that ended in Jun. 2026 was $4,786 Mil.
Envista Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $270 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Envista Holdings EV-to-EBIT Related Terms
Envista Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Envista Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Envista Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Envista Holdings EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Envista Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Envista Holdings's EV-to-EBIT falls into.
Envista Holdings's current Enterprise Value is $5,042 Mil.
Envista Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $270 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Envista Holdings (NVST) has a EV-to-EBIT of 18.71 as of Aug. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Envista Holdings and its competitors. This is 16% below median its historical median of 22.33. According to the industry distribution chart, Envista Holdings ranks #275 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 58.6%.
Is Envista Holdings' EV-to-EBIT too high?
Envista Holdings' current EV-to-EBIT of 18.71 is 16% below median its 10-year median of 22.33. The Medical Devices & Instruments industry median EV-to-EBIT is 18.89. Envista Holdings' value of 18.71 is 1% below this industry median. Based on the distribution chart, Envista Holdings ranks #275 out of 469 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Envista Holdings has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Envista Holdings' EV-to-EBIT compare to MMSI and ICUI?
According to the Medical Devices & Instruments industry distribution chart, Envista Holdings ranks #275 out of 469 companies for EV-to-EBIT. This places Envista Holdings in the lower half of its industry. The industry median EV-to-EBIT is 18.89. Envista Holdings' value of 18.71 is 1% below this benchmark. While the company's 10-year median is 22.33 vs. the industry median of 18.89, Envista Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.89, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Envista Holdings's current EV-to-EBIT of 18.71 is 1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Envista Holdings and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Envista Holdings's current EV-to-EBIT is 18.71, which is 16% below median its own 10-year median of 22.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envista Holdings stock overvalued right now?
Based on GuruFocus' analysis, Envista Holdings (NVST) is currently considered Modestly Overvalued. The stock's GF Value™ is $23.94, compared to a current price of $27.87 — trading 16.4% above its estimated fair value. The current EV-to-EBIT is 18.71, which is 16% below median its 10-year median of 22.33 and 1% below the Medical Devices & Instruments industry median of 18.89. Envista Holdings' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Envista Holdings (NVST), the current EV-to-EBIT is 18.71 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Envista Holdings (NVST) Overvalued in 2026?
Based on GuruFocus' analysis, Envista Holdings stock appears to be overvalued.
The current stock price of $27.87 is trading 16.4% above its estimated GF Value™ of $23.94.
GuruFocus considers Envista Holdings to be Modestly Overvalued.
Key valuation signals for NVST:
EV-to-EBIT: 18.71 (16% below median its 10-year median of 22.33)
GF Value™: $23.94 vs. price of $27.87 (16.4% above fair value)
Industry Position: 1% below the Medical Devices & Instruments median (#275 of 469)
No single metric tells the full story. See the NVST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
79GF Score
Get the complete analysis for NVST
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVST has been successfully added to your 
